Document:

Exhibit 10.4

 

WAIVER AGREEMENT

 

THIS WAIVER AGREEMENT (this
“Agreement”), dated as of February 4, 2022, is among New York City REIT, Inc., a Maryland corporation (the “Company”),
Bellevue Capital Partners, LLC (“Bellevue”) and New York City Advisors, LLC (the “Advisor”), the
Company’s advisor and an entity controlled by Bellevue. Capitalized terms used but not defined herein shall have the meanings ascribed
to them in the Rights Agreement (as defined below).

 

RECITALS

 

WHEREAS, the Company is a
party to an Amended and Restated Rights Agreement, dated as of August 17, 2020, as amended by Amendment No. 1, dated as of August 12,
2021 (as amended, the “Rights Agreement”).

 

WHEREAS, under Section 1.1
of the Rights Agreement, a Person is deemed to be an “Acquiring Person” if and when a Person who or which, together with all
Affiliates and Associates of the Person, is or becomes on or after the Close of Business on August 17, 2020 the Beneficial Owner of 4.9%
or more of the shares of Common Stock then outstanding (the “Ownership Threshold”), subject to certain exceptions.

 

WHEREAS, the Rights Agreement
grants the Board of Directors or a committee thereof, the authority to permit a Person to exceed the Ownership Threshold without being
deemed an Acquiring Person by means of a written waiver or agreement, provided that (x) the Person does not, prior to the waiver or agreement,
exceed the Ownership Threshold and complies in all material respects with the terms and the conditions of the waiver or agreement and
(y) the waiver or agreement remains in full force and effect.

 

WHEREAS, the Company previously
granted Bellevue a waiver from the Rights Agreement permitting Bellevue to Beneficially Own, together with all of its Affiliates and Associates,
up to 9.8% of the shares of Common Stock then outstanding.

 

WHEREAS, as of the date hereof,
Bellevue, together with all of its Affiliates and Associates, including the Advisor, Beneficially Owns less than 9.8% of the outstanding
shares of Common Stock.

 

WHEREAS, Section 5.7 of the
Charter contains limitations on the ownership of shares of the Company’s stock, which prohibit any Person from Beneficially Owning
or Constructively Owning (each as defined in the Charter) more than 9.8% in value of the aggregate of the outstanding shares of the Company’s
stock (the “Overall Limit”) or more than 9.8% (in value or in number of shares, whichever is more restrictive) of any
class or series of shares of the Company’s stock (the “Series Limit,” and collectively with the Overall Limit,
the “Aggregate Share Ownership Limit”), except as otherwise waived by the Company.

 

WHEREAS, Bellevue and the
Advisor have expressed to the Board of Directors an interest in potentially increasing their respective ownership of shares of Common
Stock through a combination of open-market purchases and the investment in shares of Common Stock by the Advisor of fees earned by the
Advisor under the Second Amended and Restated Advisory Agreement, dated as of November 16, 2018 (as amended by the First Amendment thereto,
dated as of August 18, 2020, the “Advisory Agreement”), by and among the Company, the Operating Partnership and the
Advisor.

 

WHEREAS, to enhance the Company’s
cash resources, the Advisor has expressed a willingness to, by entering into a side letter (the “Side Letter”) with
the Company and the Operating Partnership, invest, for a period of up to six months, any cash payments aggregating no more than $3.0 million
that the Advisor is paid under Section 10(c) of the Advisory Agreement in shares of Common Stock if the Company would provide: (i) a waiver
(the “Charter Ownership Waiver”) from the Aggregate Share Ownership Limit contained in Section 5.7 of the Charter to permit
Bellevue, the Advisor and certain other Persons to, Beneficially Own or Constructively Own (each as defined in the Charter) shares of
Common Stock in an amount up to 20% of the outstanding shares of Common Stock (subject to certain constraints for each such Person on
the total actual ownership of shares of Common Stock by such Persons that equals 20% of the outstanding shares of Common Stock in the
aggregate), to the extent and on the terms to be set forth in the applicable Charter Ownership Limit Waiver Agreement (as defined below);
and (ii) a further waiver from the limitations contained in Section 1.1 of the Rights Agreement (“Rights Plan Ownership Waiver,”
and collectively with the Charter Ownership Waiver, the “Ownership Waiver”) permitting the parties to the Charter Ownership
Limit Waiver Agreements to Beneficially Own shares of Common Stock to the extent allowed by the Charter Ownership Waiver without being
deemed an “Acquiring Person” under Section 1.1 of the Rights Agreement.

 

     

     

    

 

WHEREAS, the Board of Directors
has adopted resolutions approving, among other things, a change in the Ownership Threshold consistent with Bellevue and the Advisor’s
request on the terms and conditions hereinafter set forth and has determined that doing so is in the best interest of the Company.

 

WHEREAS, concurrent with the
execution of this Agreement, the Company and the Operating Partnership will enter into the Side Letter with the Advisor.

 

WHEREAS, concurrent with the
execution of this Agreement, the Company will enter into separate ownership limit waiver agreements (collectively, the “Charter
Ownership Limit Waiver Agreements”) with each Person set forth in Annex A (each, an “Excluded Person”)
with respect to the Charter Ownership Waiver.

 

WHEREAS, this waiver shall
become effective as of the date of this Agreement (the “Determination Date”).

 

NOW, THEREFORE, the parties,
for good and other valuable consideration, hereby agree as follow:

 

AGREEMENT

 

1. WAIVER OF EXISTING OWNERSHIP THRESHOLD AND REVISED THRESHOLD

 

1.1        

The Company hereby waives
the application against each Excluded Person of the existing Ownership Threshold (the “Ownership Threshold Waiver”)
contained in Section 1.1 of the Rights Agreement and each Excluded Person shall be permitted, at its discretion, to Beneficially Own
shares of the Common Stock in excess of the Ownership Threshold to the maximum extent allowed by the applicable Charter Ownership Limit
Waiver Agreement (the “Revised Threshold”).

 

1.2        The Ownership Threshold Waiver and Revised Threshold granted by this
Section 1 are granted solely for the benefit of the Excluded Persons and may not be assigned or transferred, including by operation
of law or in connection with a merger, consolidation, transfer of equity interests, by any Excluded Person without prior written consent
of the Company.

 

1.3       In
the event an Excluded Person Beneficially Owns, together with all of its Affiliates and Associates, more than the Ownership
Threshold but not exceeding the Revised Threshold, as of the date on which the Charter Ownership Limit Waiver Agreement is
terminated (the “Termination Date”), the Excluded Person shall be deemed to be a “Grandfathered
Stockholder” as defined in Section 1.1 of the Rights Agreement with respect to shares of Common Stock Beneficially Owned as of
the Close of Business on the Termination Date (the “Termination Date Percentage”); provided, however, that if the
Excluded Person becomes, after the Close of Business on the Termination Date, the Beneficial Owner of any additional shares of
Common Stock (other than shares of Common Stock acquired solely as a result of corporate action of the Company not caused, directly
or indirectly, by the Excluded Person) at any time such that the Excluded Person’s Beneficial Ownership, together with its
Affiliates and Associates, thereby exceeds the Termination Date Percentage based on the shares of Common Stock then outstanding,
then the Grandfathered Stockholder shall be deemed an Acquiring Person, unless any further waiver is granted by the Board of
Directors to the Excluded Person; provided, further, that upon the first decrease of the Excluded Person’s Beneficial
Ownership below the Termination Date Percentage, the Excluded Person shall no longer be considered a Grandfathered Stockholder and
clause (vi) of Section 1.1 of the Rights Agreement shall have no further force or effect with respect to the Excluded Person.

 

     

     

    

 

1.4       Except
as specifically provided in this Section 1, all of the terms and provisions of the Rights Agreement shall remain in full force
and effect.

 

2. REPRESENTATIONS OF THE EXCLUDED PERSONS

 

2.1       As
of the Determination Date, Bellevue, together with all of its Affiliates and Associates, Beneficially Owns less than 9.8% of the outstanding
shares of Common Stock.

 

2.2        Each
Excluded Person understands that the Common Stock remains subject to the restrictions and limitations set forth in the Charter Ownership
Limit Waiver Agreements.

 

3. TERM

 

3.1       The
term of this Agreement shall commence as of the Determination Date and shall be conterminous with the Charter Ownership Limit Waiver Agreement.

 

4. MISCELLANEOUS

 

4.1       All
questions concerning the construction, validity and interpretation of this Agreement shall be governed by and construed in accordance
with the domestic laws of the State of Maryland, without giving effect to any choice of law or conflict of law provision (whether of the
State of Maryland or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than the State of
Maryland.

 

4.2        All
notices or other communications given pursuant this Agreement shall be in writing, including by email or by verifiable facsimile transmission,
and if sent to Bellevue, shall be delivered to:

 

Bellevue Capital Partners, LLC

222 Bellevue Avenue

Newport, Rhode Island 02840

Attention: Michael Anderson

Email: manderson@ar-global.com

  

if to the Company,
shall be delivered to:

 

New York City REIT,
Inc.

650 Fifth Avenue,
30th Floor

New York, New York 10019

Attention: Legal Department

Fax No. (646) 861-7743

 

if to the Advisor,
shall be delivered to:

 

New York City Advisors,
LLC

650 Fifth Avenue,
30th Floor

New York, New York 10019

Attention: Legal Department

Fax No. (646) 861-7743

 

     

     

    

 

4.3       This
Agreement may be signed by the parties in separate counterparts, each of which when so signed and delivered shall be an original, but
all such counterparts shall together constitute one and the same instrument.

 

4.4       The
Recitals to this Agreement are incorporated into and are deemed a part of this Agreement.

 

[Signature Page Follows]

 

     

     

    

 

Each of the parties has caused this Agreement to
be signed by its duly authorized officers as of the date set forth in the introductory paragraph hereof.

 

	 	NEW YORK CITY REIT, INC.
	 	 	 
	 	By:	/s/ Christopher J. Masterson
	 	 	Name: 	Christopher J. Masterson
	 	 	Title: 	Chief Financial Officer and Treasurer
	 	 	 
	 	NEW YORK CITY ADVISORS, LLC
	 	 	 
	 	By:	/s/ Michael Anderson
	 	 	Name: 	Michael Anderson
	 	 	Title: 	Authorized Signatory
	 	 	 
	 	BELLEVUE CAPITAL PARTNERS, LLC
	 	 	 
	 	By:	/s/ Michael Anderson
	 	 	Name: 	Michael Anderson
	 	 	Title: 	Authorized SignatoryOPERATIONS AGREEMENT

Date:	January 28, 2022

Parties:	

	“PTG”	
    Predictive Technology Group, Inc., a Nevada corporation

    615 Arapeen Drive, Suite 300, Salt Lake City, UT 84108

     

	“PBI”	
    Predictive Biotech, Inc., a Utah corporation

    615 Arapeen Drive, Suite 300, Salt Lake City, UT 84108

     

	“HLTT”	
    Healthtech Solutions, Inc., a Utah corporation

    181 Dante Avenue, Tuckahoe, NY 10707

     

	“HWC”	
    Healthtech Wound Care, Inc., a Delaware corporation

    181 Dante Avenue, Tuckahoe, NY 10707 

 

Each of the foregoing is referred to herein as a “Party,”
and collectively as the “Parties,” to this Agreement.

Premises:

		A.	The Parties are executing this Operations Agreement pursuant to the terms of the Asset Purchase Agreement
among HLTT, HWC, PBI and PTG. (the “Asset Purchase Agreement”). Capitalized terms not otherwise defined herein
shall be given the same meaning as in the Asset Purchase Agreement.

		B.	Pursuant to the terms and conditions of the Asset Purchase Agreement, PBI has sold its Wound Care Assets
to HWC. The Parties desire, however, that PBI retain the capacity to engage in the Wound Care Business.

		C.	HLTT has agreed to provide financing to PBI and has also agreed to make certain loans to PTG and PBI.

Agreement:

			I. CONDUCT OF BUSINESS

1.1       PBI
License. HWC hereby grants to PBI a royalty-free, paid-up, non-transferrable or sub-licensable except to an Affiliate,
perpetual (except as set forth in the final sentence of this Section) license, to use the Transferred Assets, including the
Transferred Intellectual Property Rights, for the purpose of conducting PBI’s Wound Care Business and Non-Wound Care Business; provided,
however, that PBI’s conducting Non-Wound Care Business does not interfere in any material way with the conduct of the
Wound Care Business by PBI and HWC. For purpose of this agreement, “Affiliate” shall mean any entity that
is under control of, that controls, or is under common control with PBI. The license granted in this Section 1.1, as it relates to
Non Wound Care Business, shall continue in full force even after a transfer by HWC of the Transferred Assets, or any part of them,
to a third party. The license in this Section 1.1 of Transferred Assets other than Transferred Intellectual Property Rights shall
terminate upon the purchase of PBI by either HLTT or HWC.

    	 	 1 of 8	 

    	 

1.2       HWC License.
PBI hereby grants to HWC a royalty-free, paid-up, non-transferrable or sub-licensable except to an Affiliate, perpetual license, to use
the Intellectual Property Rights included in the Excluded Assets, including the Non Wound Care Intellectual Property, for the purpose
of conducting HWC’s Wound Care Business; provided, however, that HWC’s use of the Intellectual Property Rights included
in the Excluded Assets to conduct Wound Care Business does not interfere in any material way with the use of such Rights by PBI to conduct
Non Wound Care Business. For purpose of this agreement, “Affiliate” shall mean any entity that is under control
of, that controls, or is under common control with HWC. The license granted in this Section 1.2 shall continue in full force even after
a transfer by PBI of the Excluded Assets, or any part of them, to a third party.

1.3       Professional
Personnel. PBI must have among its employees a Person of Primary Responsibility and other licensed or accredited individuals in
order to maintain and renew the permits under which it conducts biomedical research and manufactures Wound Care products. HWC aspires
to conduct biomedical research and to manufacture Wound Care products, and so will require employees with similar credentials. The Parties
agree, therefore, that they will cooperate in allocating between PBI and HWC the services of professional personnel as needed to achieve,
maintain, and renew the regulatory permits governing each of them.

1.4       Wound Care
Sales. By letter to HLTT dated December 30, 2021, the CEO of PTG identified certain “Specified Accounts”.
During the Term of this Agreement, PBI shall market and sell Wound Care products only to Specified Accounts, and PBI shall direct the
Specified Accounts to make payment for such products to an account owned by HWC. PBI will also fill orders for Wound Care products as
requested by HWC, with payment directed to an account owned by HWC. HWC shall reimburse PBI on a semi-monthly basis for its direct costs
in selling product to Specified Accounts and filling orders for HWC. The parties will meet on a bi-monthly basis to review the measurement
of direct costs.

1.5       Capacity
Allocation. Promptly after execution of this Agreement and from time to time thereafter as needed, PBI and HWC shall agree upon
the production capacity of the combined lab facilities of PBI and HWC dedicated to the Wound Care Business (the “Capacity”).
On a monthly basis, twenty percent (20%) of the Capacity shall be allocated to production for sales to Specified Accounts and the remaining
eighty percent (80%) shall be allocated to production for all other sales. If on the 15th day of the preceding month sales
scheduled for production in a given month are insufficient to fill either allocation of Capacity, then the allocation shall be withdrawn
for that month to allow the shortfall to be completed by sales to any accounts.

    	 	 2 of 8	 

    	 

1.6       Leaseholds.
If, after the Date of this Agreement, PBI remains the lessee of any premises at 615 Arapeen Drive (the “PBI Premises”),
then PBI shall take all commercially reasonable steps to retain its leasehold interest in the PBI Premises through the Term of this Agreement,
except that, upon request by HWC, PBI will assist HWC in transferring the leasehold for the PBI Premises to HWC.

1.7       Patient
Records. Each of PBI and HWC shall provide the other with access to such research data in its possession, including, to the extent
permitted by applicable law, patient records, as to which the requesting party states a reasonable use in connection with its research
and development activities or its applications for licenses or permits. If applicable law requires special proceedings to authorize such
disclosure, the holder of the records will use its best efforts to assist the requestor in completing the procedures (including applications)
on a timely basis. The recipient party will maintain the confidentiality of all such records in accordance with applicable law. Notwithstanding
the foregoing, nothing in this Section 1.7 shall be deemed to transfer any ownership rights or interests in or to the patient records
to the requesting party.

			II. FINANCING OF BUSINESS

2.1       Working
Capital Commitment. HLTT will contribute working capital as needed for the conduct of the Wound Care Business by HWC and/or PBI.
HLTT will make the capital contributions to HWC, and HWC shall in turn make non-interest-bearing demand loans as needed by PBI to carry
on its Wound Care Business. HLTT’s obligation to contribute working capital to HWC (for itself or for PBI) will terminate upon
the earlier of these events:

		a)	HWC is Cash Flow Positive. HWC will be considered “Cash Flow Positive” on
the last day of any period of six consecutive months if the cash flow from operations realized by HWC for that six-month period, in accordance
with generally accepted accounting principles, is positive.

		b)	the aggregate capital contributions by HLTT to HWC equal Three Million Five Hundred Thousand Dollars
($3,500,000). 

		c)	HLTT shall have reasonably determined and notified PTG in writing that market conditions make it unlikely
that HWC will be financially successful in the Wound Care Business (an “Abandonment”). 

2.2       Reversion.
Upon receipt of notice of Abandonment by HLTT and at any time during the sixty (60) days following receipt of such notice, PTG may
give HLTT written notice that it will make a good faith effort to assist HWC in achieving financial success, which notice shall be
accompanied by a budget for the effort and an identification of sources of financing. Upon HLTT’s receipt of that notice with
the requisite information, a “Reversion” shall be implemented. HLTT shall transfer to PTG managerial
control of HWC, and PTG shall implement its commitment to a good faith effort. If within three years after commencement of the
Reversion, HWC achieves Cash Flow Positive, as defined above, then HLTT will assign t PTG that number of shares of HWC common stock
as will cause the ratio of common stock owned by PTG (excluding common stock issued on conversion of Series A Preferred Stock) to
common stock owned by HLTT to equal the ratio of PTG’s capital contributions to HWC to HLTT’s capital contributions to
HWC.

    	 	3 of 8	 

    	 

2.3       Buyout.
If either (a) HLTT gives notice of Abandonment to PTG that is not followed by a Reversion or (b) within three years after commencement
of a Reversion, HWC has not achieved a Cash Flow Positive period at any time, then at any time thereafter (if but only if HWC has not
at any time achieved a Cash Flow Positive period) either HLTT or PTG (the “Offeror”) may give written notice
to the other (the “Recipient”) of a “Buyout”. The notice of Buyout shall state a
per common share price (applicable to convertible securities on an as-converted basis) at which the Offeror offers to both (1) purchase
the HWC securities owned by the Recipient, and (2) sell to the Recipient the HWC shares owned by the Offeror, at the option of the Recipient.
Within forty days after receipt of the notice of Buyout, the Recipient will respond in writing stating its choice to purchase the Offeror’s
shares or sell the Recipient’s shares at the price set forth in the notice of Buyout. If the Recipient fails to respond in writing
within forty days, then the Recipient will be deemed to have agreed to sell its HWC shares to the Offeror. The closing of the purchase
and sale will take place at the executive offices of HWC on the thirtieth day after Offeror receives Recipient’s notice (or seventy
days after notice of Buyout was given, if the Recipient fails to respond) or the first business day thereafter. At the closing, the seller
will deliver a stock power and certificate (if issued) transferring its HWC shares to the buyer, and the buyer will deliver the purchase
price. Unless otherwise agreed by the parties, the purchase price may be paid in cash or in any combination of cash (not less than twenty
percent of the purchase price) and promissory note. Unless otherwise agreed to by the parties, the promissory note shall:

		a.	have such maturity date as the purchaser chooses, which shall be no more than three years after the
closing date;

		b.	provide for quarterly amortization of the principal amount of the Promissory Note;

		c.	bear interest at six percent (6%) per annum, payable quarterly; and

		d.	be secured by a pledge of the purchased shares.

The promissory note shall be accompanied by a pledge agreement
covering the purchased shares, which shall contain standard commercial pledge terms for a pledge of equity securities issued by a privately
held entity.

2.4       Right of
Participation. If, at any time after the Conversion of the Series A Preferred Stock to Common Stock of HWC, HWC proposes to issue
equity securities in exchange for cash, HWC will so notify PTG and will afford to PTG the opportunity to purchase such portion of the
offered securities as equals the portion of HWC’s fully-diluted common shares owned by PTG. HWC will hold the offer open for no
less than five business days, during which PTG must designate the number of securities, if any, it chooses to purchase. Payment for such
securities will be due according to the schedule applicable to the offering.

    	 	4 of 8	 

    	 

			III.
                                            PTG LOANS AND THE ROYALTY

 

3.1       Loans.
Commencing in December 2021, HLTT has loaned a total of Two Hundred Fifty Thousand Dollars ($250,000) to PTG and PBI jointly. Within one
week after a Q Code is issued to PBI providing for reimbursement of patient sales of Amniobind at a rate equal to or exceeding $100 per
cm2, HLTT shall pay $250,000 to PTG as a loan to PTG and PBI jointly (the “Q Code Loan”). The existing
$250,000 obligation and the Q Code Loan, if it occurs, are identified herein as “PTG Loans”. The PTG Loans shall
be the joint and several obligations of PTG and PBI, except that if HLTT or HWC purchases the outstanding capital stock of PBI, then the
PTG Loans will be the obligation of PTG solely. The PTG Loans will not bear interest.

3.2       Commission.
HWC shall pay to PBI (but if HLTT or HWC owns PBI, then HWC shall pay to PTG) a commission on sales to the Specified Accounts, payable
monthly on the tenth day following the month. HWC shall reserve and pay over to HLTT twenty-five percent (25%) of all commissions due
hereunder as a credit against the PTG Loans until same are fully satisfied. Commissions shall be calculated as a percentage of Gross Income
from such sales, according to measuring principals to which the Parties agree from time to time. The percentage of Gross Income to be
paid as commission shall be measured on the date of the first commercial sale to any account after issuance of the Q Code and then on
each anniversary of that date as follows:

	Measuring Date	Commission %
	First Sale	20%
	Third Anniversary	18%
	Fourth Anniversary	16%
	Fifth Anniversary	14%
	Sixth Anniversary	12%
	Seventh Anniversary	10%
	Eighth Anniversary	8%
	Ninth Anniversary	6%

Commissions on sales after the tenth year shall be paid at industry
standard rates for sales commissions on sales to the Specified Accounts or similar accounts. For purposes of this Section 3.2, “Gross
Income” shall equal Net Sales less the Direct Costs of Production, where (a) Net Sales means gross sales less returns, allowances
and discounts, and (b) “Direct Costs of Production” means costs of placental tissue, direct labor, supplies (such as sterile
saline, RO water, pipettes, gauze pads and forceps, etc.), irradiation, packaging, and cost of delivery.

			IV. NON WOUND CARE BUSINESS

4.1       License
of Future Wound Care Applications. Except as specifically set forth in this Section IV, PBI may continue and grow its Non
Wound Care Business. PBI’s Non Wound Care Business may in the future yield therapies, products, or Intellectual Property
Rights suitable for Wound Care applications (“Future Wound Care Applications”). If a Future Wound Care
Application is developed during the Term of this Agreement, PBI grants to HWC a royalty-free, paid-up, non-transferrable or
sub-licensable except to an Affiliate, perpetual license to use such Future Wound Care Application strictly for HWC’s Wound
Care Business. The license granted in this Section 4.1 for the Future Wound Care Application shall continue in full force even after
a transfer by PBI or PTG of the Intellectual Property Rights that include the Future Wound Care Application to a third party.

    	 	5 of 8	 

    	 

4.2       Transfers.
PTG may at any time transfer some or all Non Wound Care Business and Non Wound Care Assets from PBI to PTG or to another subsidiary or
affiliate of PTG. If HLTT or HWC acquires ownership of PBI, PTG shall transfer all Non Wound Care Business and Non Wound Care Assets
from PBI to PTG or to another subsidiary or affiliate of PTG on or before January 31, 2025. In each of the foregoing cases, the transfer
of assets shall be accompanied by any debt specifically attributable to such assets, such as purchase money debt or debt underlying secured
liens. The rights and obligations of Sections 4.1 and 4.3 shall continue notwithstanding a transfer pursuant to this Section 4.2.

4.3       ROFO.

4.3.1.       Prior to engaging
(directly or through a subsidiary) in any substantive negotiation with a third party regarding any proposed transfer of any Non Wound
Care Assets or any portion of the Non Wound Care Business, PTG must deliver a written notice to HLTT setting forth its intent to negotiate
(such notice, a “Transaction Notice”). The Transaction Notice need not set forth the identity of the third party but must
set forth the assets and/or business the negotiations are expected to cover. Upon receipt of the Transaction Notice, HLTT shall have 30
days (the “Offer Period”) in which to make a firm offer to purchase the assets and/or business set forth in the Transaction
Notice (an “Offer”). Upon receipt of the Offer and during the Offer Period, PTG and HLTT shall engage in non-binding
discussions and negotiations in good faith to attempt to agree on definitive terms acceptable to both Parties, in their sole and absolute
discretion, for the purchase of the applicable Non Wound Care Business or Assets to HLTT or a subsidiary of HLTT. If, by the end of the
Offer Period, the Parties have not agreed to definitive terms for the transfer purchase and sale, PTG will have the right, within the
270 days following such Offer Period (the “Third Party Transfer Period”), to consummate a transfer of such Non Wound Care
Business or Assets to a third party (or agree in writing to undertake such transfer to a third Party) in accordance with the terms of
Section 4.3.2.

4.3.2       Neither
PTG nor any of its representatives, agents or affiliates shall solicit offers from, or negotiate or enter into any agreement with,
any third party for the transfer of any Non Wound Care Business or Assets (or any portion thereof) until the expiration of the Offer
Period. HLTT agrees and acknowledges that during the Third Party Transfer Period for any Non Wound Care Business or Assets and the
applicable proposed transfer: (a) PTG shall have the absolute right to solicit offers from, negotiate with, and enter into
agreements with, any third party for the transfer of such Non Wound Care Business or Assets, on terms in all material respects no
less favorable to PTG than those offered by HLTT, and (b) PTG shall have no further obligation to negotiate with HLTT regarding, or
offer HLTT the opportunity to acquire any interest in, such Non Wound Care Business or Assets; provided, that the final terms of the
transfer to any third party be on terms in all material respects no less favorable to PTG than those offered to HLTT; provided
further, that following any Third Party Transfer Period for any Non Wound Care Business or Asset during which no agreement was
entered into for a transfer to a third party, if such Third Party Transfer Period ends on or before January 31, 2025, PTG shall
comply with Section 4.3.1 (including by delivering a Transaction Notice and negotiating during the Offer Period) prior to continuing
or entering into new negotiations with a third party regarding the transfer of any Non Wound Care Business or Assets to a third
party.

    	 	6 of 8	 

    	 

4.3.3 HLTT’s rights of first offer, as set forth in
this Section 4.3, shall terminate on January 31, 2025, and PTG shall have no obligations under this Section 4.3 as to any third-party
negotiations that commence after January 31, 2025.

			V.
                                            MISCELLANEOUS

 

5.1        Term.
The “Term” of this Agreement will commence on the date written on its first page and will end on January 31, 2027.

5.2       Non
Competition. Except to the extent specifically authorized in this Agreement, PTG shall not, nor shall it permit any subsidiary
or affiliate to, engage in the marketing of Wound Care products or therapies that are Directly Competitive with products or therapies
for Wound Care applications being then marketed by HWC. A product or therapy marketed by PTG will be deemed to be “Directly
Competitive” with a product or therapy marketed by HWC if the PTG product or therapy is used to eliminate a sign of a wound;
a PTG product or therapy will not be deemed to be Directly Competitive by reason of use of the PTG product or therapy to eliminate or
prevent a cause or symptom of a wound.

5.3       Confidentiality.
Each party recipient of confidential information about a disclosing party agrees to keep the disclosing party’s confidential information
strictly confidential, provided, however, that the obligation will terminate as to any information that becomes generally available to
the biomedical research community.  The parties agree that a breach of confidential information constitutes an irreparable harm and
that an injured party may seek all available judicial relief, including but not limited to injunction and damages.  Parties may share
confidential information with their attorneys, employees, investors, accountants, and agents so long as these are bound to confidentiality
by a written agreement containing terms at least as strict as those herein. 

(This
is intentionally blank. Signature page follows.)

 

 

    	 	 7 of 8	 

    	 

In witness whereof, the
Parties have executed this Agreement,

	PREDICTIVE TECHNOLOGY GROUP, INC.	HEALTHTECH SOLUTIONS, INC.
	
    By: /s/ Bradley C. Robinson

    Bradley C. Robinson, CEO
	
    By: /s/ Manuel E. Iglesias

    Manuel E. Iglesias, President

	PREDICTIVE BIOTECH, INC.	HEALTHTECH WOUND CARE, INC.
	
    By: /s/ Bradley C. Robinson

    Bradley C. Robinson, CEO
	
    By: /s/ Manuel E. Iglesias

    Manuel E. Iglesias, President

    	 	 8 of 8

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}]]